DIGISTAIN® is suitable for patients with breast cancer who meet the following criteria:
Stage 1 to 2 breast cancer
ER+ and HER2- (hormone receptor-positive, HER2 negative)
No more than 3 affected lymph nodes
Uses for DIGISTAIN®
Reports likelihood of breast cancer recurrence when treated with hormone therapy alone.
Determine recommended treatment
Determine whether cytotoxic therapy is required in addition to hormone therapy.
99% Reduction in patient waiting times, with actionable results in under an hour
98% Accuracy in identification of to low risk patients who could safely forego chemotherapy
30% Overall cost reduction through avoided chemotherapy
"It gives the same information about the need for chemotherapy at almost one-fourth the current costs. The new invention can help patients who have been detected with early stage breast cancer and only a few women benefit from chemotherapy at this stage."
Manish Singhal MD, DM(AIIMS)
Senior Consultant Medical Oncology at Apollo Hospitals
DIGISTAIN® demonstrated equivalence to leading NGS tumor profiling tests in a validated study of over 800 hormone positive early stage breast cancer patients. The approach of this test is based on well-established chemical analysis technology, that has not previously been used for cancer risk scoring.
